Saturday 17 October 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 22.2% and free cash flow fell 73.8%, each against the same quarter a year earlier.
11.87
0.24
−1.98%
Follow TRVI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (19.66%) | (33.59%) | (30.23%) | (36.87%) |
+8 more TTM periods Free account |
|
| (18.97%) | (31.83%) | (28.10%) | (34.19%) | ||
ROIC |
(1,412.11%) | (9,587.57%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(16.11%) | (26.95%) | (23.48%) | (24.20%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.34) | (0.31) | (0.31) | (0.30) | |
Free Cash Flow |
(52.87) | (45.42) | (42.11) | (44.05) | |
Capital Expenditures |
(0.24) | (0.12) | (0.02) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(8.26%) | (13.21%) | (11.33%) | (11.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.03 | 0.99 | 0.98 | 0.96 | |
Depreciation/Fixed assets |
0.41 | 0.53 | 0.81 | 0.71 | |
Capex/Depreciation |
(1.74) | (0.86) | (0.13) | (0.31) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.34) | (0.31) | (0.31) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates